Anti-nuscleosome antibody, a reliable indicator for lupus nephritis

Autoimmunity

Volumn 42, Issue 5, 2009, Pages 393-398

  Kiss, Emese ^a   Lakos, Gabriella ^b   Szegedi, Gyula ^c   Poor, Gyula ^a   Szodoray, Peter ^d  

^a NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; Disease activity; Lupus nephritis; Nucleosome; Systemic lupus erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; HISTONE ANTIBODY; NUCLEOSOME ANTIBODY;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; APOPTOSIS; AUTOANTIBODIES; DNA; FEMALE; HISTONES; HUMANS; HUNGARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; NUCLEOSOMES; YOUNG ADULT;

EID: 70749084153     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930903002446     Document Type: Article

References (40)

1. Van Holde KE. Chromatin. Springer series in molecular biology. In: Rich A, editor. New York, NY: Springer; 1989. p 246.
2. Kávai M, Bányai A, Zsindely A, Sonkoly I, Szegedi G. An ensyme-linked immunosorbent asssay for autoantibodies to native DNA in sera patients with systemic lupus erythematosus. J Immunol Methods 1982;48:169-175.
3. Monier JC. Antinuclear antibodies: detection and diagnostic value. Int J Rad Appl Instrum B. 1990;17:713-718.
4. Lachman PJ. An attempt to characterize the lupus erythematosus cell antigen. Immunology 1961;4:153-163.
5. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999;42:833-843.
6. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94:184-192.
7. Amoura Z, Chabre H, Koutouzov S, Lotton C, Cabrespines A, Bach JF, Jacob L. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994;37:1684-1688.
8. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibodyinducing T cells in human lupus. J Clin Invest 1995;95: 531-541.
9. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: A major target for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-1381.
10. Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995;38:1485-1491.
11. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725-1743.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;3:630-640.
13. Nagy G, Bró zik M, Tornó ci L, Gergely P. Diagnostic value of combined evaluation of neopterin and anti-DNA antibody levels for assessment of disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:699-705.
14. Abrass CK, Nies KM, Louie JS, Border WA, Glassock RJ. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1980;23:273-282.
15. Foster MH, Cizman B, Madaio MP. Nephritogenic autoantibodies in systemic lupus erythematosus: Immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 1993;69:494-507.
16. Lefkowith JB, Gilkeson GS. Nephritogenic antibodies in lupus: Current concepts and continuing controveresries. Arthritis Rheum 1996;39:894-903.
17. Bernstein KA, Valerio RD, Lefkowith JB. Glomerular binding acivity in MRL lpr serum consists of antiboies that bind to a DNA/histone/type IV collagen complex. J Immunol 1995;154: 2424-2433.
18. Fésu s L. Biochemical events in naturally occuring forms of cell death. FEBS Lett 1993;328:1-5.
19. Strasser A, Huang DC, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997;1333:151-178.
20. TaxWJ, Kramers C, van Bruggen MC, Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995;48:666-673.
21. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994;76:969-976.
22. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
23. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98: 1107-1113.
24. EmlenW, Niebur J, Kadera R. Accelareted in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-3692.
25. Van Houten N, Budd RC. Accelerated programmed cell death of MRL-lpr/lpr T lymphoyctes. J Immunol 1992;149: 2513-2517.
26. Amoura Z, Pietta JC, Chabre H, Cacoub P, Papo T, Wechsler B, Bach JF, Koutouzov S. Circulating plasmalevels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum anti-nulceosome antibody titers and absence of clear association with disease activity. Arthritis Rheum 1997;40:2217-2225.
27. Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cells undergoing apoptosis. Immunol Today 1993;14:131-136.
28. Bell DA,Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: The release of, and immunproliferative response to, nucleosomes in vitro. Clin Immunol Immunpathol 1991;60:13-26.
29. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;20:387-392.
30. Herrmann M, Voll RE, ZollerOM,Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-1250.
31. Laderach D, Bach JF, Koutouzov S. Nucleosomes inhibit phagocytosis of apoptotic tymocytes by peritoneal macrophages from MRL + /+ lupus prone mice. J Leukoc Biol 1998;64:774-780.
32. Goetz J, Humbel RL. Antinucleosome antibodies. GET AI Info 1999;1:5-8.
33. Burlingame RW, Rubin RL. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Methods 1990;134:187-199.
34. Monestier M. Autoantibodies to nucleosomes and histon/ DNA complexes. Methods 1997;11:36-43.
35. Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992; 90:165-173.
36. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, Bach JF, Piette JC. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Arthritis Rheum 2000;43:76-84.
37. Gómez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value. Autoimmun Rev 2008;7:606-611.
38. Tozzoli R. Recent advances in diagnostic technologies and their impact in autoimmune diseases. Autoimmun Rev 2007; 6:334-340.
39. Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun Rev 2002;1:321-328.
40. Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic antinucleosome antibodies. Lupus 2008;17:431-436.